• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Preparation of a drug to prevent premature aging in humans, pharmaceutical composition and compound selection method based on the use of sirna from nfkbiz. Use of a composition comprising rna molecules for the manufacture of a medicament for preventing premature aging in a human and pharmaceutical composition. Method of selecting compounds useful in the treatment of premature aging, comprising incubating renal tubular cells, determining whether the expression of nfkbiz in renal tubular cells is less than the expression of nfkbiz in a control sample and identifying a compound as a useful compound in the treatment of premature aging. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2620988A1
    申请号:ES201531933
    申请日:2015-12-30
    公开日:2017-06-30
    发明作者:Alberto ORTIZ ARDÚAN；Ana Belén SANZ BARTOLOMÉ；Maria Dolores SÁNCHEZ NIÑO；Jonay POVEDA NUÑEZ
    申请人:Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz；
    IPC主号:
    专利说明:

    image 1
    image2
    image3
    image4
    image5
    image6
    image7
    权利要求:
    Claims (1)
    [1]
    image 1
    类似技术:
    公开号 | 公开日 | 专利标题
    AU2018260825A1|2018-11-22|Compositions and Methods for Lowering Levels of High-Sensitivity | in a Subject
    CY1118611T1|2017-07-12|COMBINATIONS CONTAINING DERIVATIVES OF 6-benzyl-PHENYL-2-THEIOTETRAFDROPYRAN-3,4,5-TRIOLIS AS INHIBITORS OF cotransporter 1 AND 2 SODIUM-GLUCOSE FOR USE IN DIABETIC PATIENTS
    CY1119575T1|2018-03-07|Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
    BR112018010923A2|2018-12-04|multispecific antibodies
    BR112017005110A2|2018-01-23|isolated monoclonal antibody or antigen-binding fragment thereof, isolated nucleic acid molecule, pharmaceutical composition, and method for lowering blood glucose levels or for treating a condition or disease.
    BR112016002496A2|2017-08-01|compound of formula i, pharmaceutical composition, method for inhibiting kdm1a, method for treating a globin-mediated disease, method for achieving an effect on a patient, and method for inhibiting at least one function of kdm1a
    Chiu et al.2017|GPNA inhibits the sodium-independent transport system L for neutral amino acids
    CR20140161A|2014-06-03|BENZILINDAZOLS REPLACED FOR USE AS INHIBITORS OF QUINASA BUB1 IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
    BR112015029788A2|2017-09-26|hetero-multimer, isolated antibody construct, nucleic acid, host cell, method for preparing the hetero-multimer, pharmaceutical composition, method for treating a disease, use of the hetero-multimer, use of a therapeutic amount of the hetero-multimer, and method for reduce effector function of an antibody construct
    MX358517B|2018-08-24|Methods for determining drug efficacy using cereblon-associated proteins.
    BR112013028779A2|2017-08-01|antigen or immunoconjugate binding protein, immunoconjugate, pharmaceutical composition, method for treating a human patient afflicted with an inflammatory disorder or disease, and use of a composition
    UA117659C2|2018-09-10|Rspo3 binding agents and uses thereof
    BR112018001534A2|2018-09-11|mutant isocitrate dehydrogenase inhibitor idh1 r132h
    BR112015030918A2|2017-12-05|method for producing renal progenitor cells, and drugs containing renal progenitor cells
    EA201200046A1|2012-08-30|NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND RELATED METHODS
    BR112016024421A2|2017-08-15|pharmaceutical composition, capsule and use of pharmaceutical composition
    CO2017002400A2|2017-07-28|Compositions and methods for detection of smn protein in a subject
    PH12018500762A1|2018-10-29|Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
    BR112017025459A2|2018-08-07|composition, method for treating sickle cell disease, kit, method for detection of sodium pentosan polysulfate |
    ES2620988A1|2017-06-30|Elaboration of a medicine to prevent premature aging in humans, pharmaceutical composition and method of selection of compounds based on the use of sirna by nfkbiz |
    ES2524516A1|2014-12-09|Procedure for the preparation of human albumin with reduced dissolved oxygen level |
    BR112013029645A2|2022-02-01|Respiratory infection disease diagnosis using blood samples
    TR201908937T4|2019-07-22|Indanyl urea compounds that inhibit P38 MAP kinase.
    BR112016008288A2|2017-09-26|soluble gamma fc receptor for treatment of bullous autoimmune diseases
    ES2560902A2|2016-02-23|Method for determining degree of modified potency of a medicament
    同族专利:
    公开号 | 公开日
    ES2620988B1|2018-04-23|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US20060275294A1|2002-08-22|2006-12-07|Omoigui Osemwota S|Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer|
    US20070099252A1|2005-10-25|2007-05-03|Batheja Ameesha D|Diagnostic application of mail|
    法律状态:
    2018-04-23| FG2A| Definitive protection|Ref document number: 2620988 Country of ref document: ES Kind code of ref document: B1 Effective date: 20180423 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201531933A|ES2620988B1|2015-12-30|2015-12-30|PREPARATION OF A MEDICINAL PRODUCT TO PREVENT PREMATURE AGING IN HUMANS, PHARMACEUTICAL COMPOSITION AND COMPOSITE SELECTION METHOD BASED ON THE USE OF NFKbiz SYRNA|ES201531933A| ES2620988B1|2015-12-30|2015-12-30|PREPARATION OF A MEDICINAL PRODUCT TO PREVENT PREMATURE AGING IN HUMANS, PHARMACEUTICAL COMPOSITION AND COMPOSITE SELECTION METHOD BASED ON THE USE OF NFKbiz SYRNA|
    [返回顶部]